MicroGenDX First Independent Commercial Lab in US Offering NGS for Infections to Appeal Directly to Patients
January 24, 2022 18:07 ET
|
Microgen Diagnostics
ORLANDO, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Using national TV, radio, and web media campaigns, Microgen Diagnostics will be the first independent commercial lab in the U.S. to appeal directly...
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
January 03, 2022 17:07 ET
|
Interpace Biosciences, Inc.
Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”)...
Rome Foundation Releases Clinical Criteria to Better Meet Needs of Patients
November 29, 2021 09:00 ET
|
Rome Foundation
RALEIGH, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation has published a groundbreaking modification of the Rome IV diagnostic criteria of the Disorders of Gut Brain Interaction (DGBI -...
$712.91Mn by 2028 Photomedicine Devices and Technologies Market Size Lead by Photodynamic Therapy (5.3% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
November 24, 2021 07:05 ET
|
The Insight Partners
New York, Nov. 24, 2021 (GLOBE NEWSWIRE) -- According to our new research study on Photomedicine Devices and Technologies Market Size, Share, Revenue, Growth, Trends, Forecast to 2028 - COVID-19...
Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results
November 10, 2021 16:05 ET
|
Interpace Biosciences, Inc.
●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly...
Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related Conditions
October 28, 2021 08:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Vietnam leads the way with SOS Stool Method to diagnose TB
October 28, 2021 08:00 ET
|
KNCV Tuberculosis Foundation
Vietnam, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vietnam is the first country in the world to routinely use an innovative method to diagnose tuberculosis (TB) using stool. The Simple One-Step Stool...
Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank
October 15, 2021 09:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a...
Philips introduces next-generation Digital Pathology Suite - IntelliSite - to enhance diagnostic confidence and streamline pathology lab workflows
October 15, 2021 04:00 ET
|
Royal Philips
October 15, 2021 Solution offers high quality imaging with multi-site, multi-disciplinary interoperability, artificial intelligence and Laboratory Information System integration, enhancing...
Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results
August 10, 2021 16:05 ET
|
Interpace Biosciences, Inc.
●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company’s Highest Revenue Quarter ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating...